ScreenerHero

TRVI Trevi Therapeutics, Inc.

NAS · US · Healthcare · Biotechnology · trevitherapeutics.com
13.14USD-0.30%Mkt Cap: 1.87B $P/E: —

Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and commercializes investigational therapy for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF) and non-IP…

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$128.08BUSDP/E 29.4
MRNA
Moderna, Inc.
$78.44BUSD
REGN
Regeneron Pharmaceuticals, Inc.
$76.40BUSDP/E 18.4
ARGX
argenx SE
$57.03BUSDP/E 37.3
ARGX
argenx SE
$58.08BUSDP/E 35.4
UCB
UCB SA
$42.24BUSDP/E 18.0
RVMD
Revolution Medicines, Inc.
$43.05BUSD
ONC
BeOne Medicines AG
$41.41BUSDP/E 65.1
RPRX
Royalty Pharma plc
$32.80BUSDP/E 30.2
ALNY
Alnylam Pharmaceuticals, Inc.
$30.03BUSDP/E 37.8
ROIV
Roivant Sciences Ltd.
$25.10BUSD
BNTX
BioNTech SE
$23.93BUSD
INCY
Incyte Corporation
$22.99BUSDP/E 14.5
GMAB
Genmab A/S
$22.27BUSDP/E 30.7
GMAB
Genmab A/S
$22.54BUSDP/E 28.9
INSM
Insmed Incorporated
$22.22BUSD
ASND
Ascendis Pharma A/S
$15.03BUSDP/E 17.5
JAZZ
Jazz Pharmaceuticals plc
$15.01BUSDP/E 15.8
EXEL
Exelixis, Inc.
$14.48BUSDP/E 18.4
SMMT
Summit Therapeutics Inc.
$14.32BUSD

Key Statistics

Company
Market Cap1.87B USD
Enterprise Value1.56B USD
Revenue (TTM)—
Gross Profit—
Net Income (TTM)-42.76M USD
Revenue/Share—
Last Price13.14 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees34
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-22.84
PEG—
EV/EBITDA-26.25
EV/Revenue—
P/S—
P/B5.84
EPS (TTM)-0.34
EPS (Forward)-0.58
52W Range
8.24041% of range20.15
52W High20.15 USD
52W Low8.240 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE-23.33%
ROA-22.10%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-42.09M USD
CapEx (TTM)12.00K USD
FCF Margin—
FCF Yield-1.78%
Net Debt-318.27M USD
Net Debt/EBITDA5.36
Balance Sheet
Debt/Equity0.00
Current Ratio37.28
Quick Ratio36.68
Book Value/Sh2.26 USD
Cash/Share2.24 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio—
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating1.2 (Strong Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)28.18 USD
Upside (mean)+114.5%
Target Range23.00 USD – 40.00 USD
23.00+114.5% to mean40.00
# Analysts11
Ownership
Shares Out.142.48M
Float118.32M
Insiders0.63%
Institutions107.73%
Short Interest
Short Ratio8.3d
Short % Float9.40%
Short % Out.8.47%
Shares Short12.07M
Short (prev mo.)12.66M
Technical
SMA 5016.78 (-21.7%)
SMA 20014.27 (-7.9%)
Beta0.98
S&P 52W Chg16.45%
Avg Vol (30d)1.82M
Avg Vol (10d)1.90M
Technical Indicators
RSI (14)22.0
MACD-0.9769
MACD Signal-0.8659
MACD Hist.-0.1110
BB Upper17.25 USD
BB Middle14.92 USD
BB Lower12.60 USD
BB Width31.15%
ATR (14)0.6993 USD
Vol Ratio (20d)2.79x